Product
ONX 0801
Licensee
Onyx Pharmaceuticals
Indication
Solid tumours
Phase
Late preclinical
Description
Novel Thymidylate Synthase (TS) inhibitor
Further Information
ONX 0801 is designed to work by combining two proven approaches to improving outcomes for cancer patients. These include receptor-mediated targeting of tumour cells and inhibition of thymidylate synthase, a key enzyme involved in cell growth and division. ONX 0801 targets malignant cells that overexpress the alpha-folate receptor, which is located on the cell's surface. Once ONX 0801 enters the cell via this receptor, the compound inhibits, or switches off, thymidylate synthase (TS). ONX 0801 is distinct from currently marketed TS inhibitors, such as pemetrexed, 5 fluorouracil, and raltitrexed, due to its selective tumour cell-specific uptake by the alpha-folate receptor. The alpha-folate receptor is overexpressed in a number of tumour types with significant unmet needs, including ovarian cancer, lung cancer, breast cancer, and colorectal cancer.
Return to Pipeline
|